Presented on March 5th, 2021.
In August 2020, AMO Pharma published the results of a Phase 2 study utilizing AMO-02 (Tideglusib) for Childhood Onset DM1 in Pediatric Neurology. AMO Pharma is excited to announce they will be moving forward with the REACH-CDM Clinical Trial for AMO-02 after the US FDA and Health Canada approved their recently revised study protocols. Click here to learn more about AMO Pharma.
Each month biotechnology, pharmaceutical and academic partners, large and small, working on treatments and a cure for myotonic dystrophy will sit down with our community to share their progress and answer your questions. Click here to find all our upcoming Meet the DM Drug Developers dates.
About the Presenters
Joe Horrigan, Chief Medical Officer
Joe received his Sc.B. degree from Brown University and his medical degree from the University of Rochester. Joe has been a longstanding scientific advisor to FRAXA, he is a Board member of Rettsyndrome.org, and he is a member of the Angelman Syndrome Foundation Scientific Advisory Committee. Joe is also a Consulting Associate Professor at the Duke University Center for Autism and Brain Development in Durham, North Carolina. At Duke, he evaluates and treats patients in Duke’s tertiary care autism clinic.
Joe is a pediatric neuropsychiatrist, and he has specialized in the treatment of children with complex neurodevelopmental disorders for more than 30 years. Joewas a Senior Director in the Neurosciences Medicines Development Center at GlaxoSmithKline, where he also co-founded and led the company-wide Medicines for Children Advisory Network that collaborated with all therapeutic areas in the company. Dr. Horrigan also served as Assistant Vice President and Head of Medical Research for Autism Speaks, the largest science and advocacy organization in the U.S. devoted to autism spectrum disorders (ASD). He subsequently served as Vice President of Clinical Development and Medical Affairs for Neuren Pharmaceuticals Limited, leading that company’s pioneering clinical development efforts in neurodevelopmental disorders such as Rett syndrome and Fragile X syndrome, as well as in traumatic brain injury.
Mike Snape, Chief Scientific Officer
Dr Mike Snape received his BA with Honors at Oxford University, England and his PhD from London University after study at the Maudsley and Bethlem Hospital. Mike presently holds an adjunct Professorship at CASE Western university. He has more than 30 years of experience in pharmaceutical research and development and has managed relevant projects from pre-clinical through clinical stages of development. He previously worked in CNS R&D at AstraZeneca and also has extensive experience of research and development projects in the field of CNS disorders in a small life scie4nce company environment having been Principal Scientist at Cerebrus Ltd and Associate Director at Vernalis, and was a founder of Neuropharm. Mike has been an advisor to venture capital groups in the UK, the Welcome Trust and sits on the advisory council of multiple research foundations.
Mike initiated one of the first industry sponsored clinical projects in autism in 1997, lead the first industry sponsored multi-center studies of a core symptom of autism, and some of the first industry sponsored studies in Fragile X Syndrome. More recently Mike was one of the founders of AMO Pharma Ltd. AMO Pharma submitted the first successful application for Fast Track Status for congenital myotonic dystrophy program to be granted by the FDA.
Emily Fantelli, Associate Director, Clinical Development
Emily is studied biology at Pacific Lutheran University and then did graduate studies at the University of Washington, Seattle. After working as an Emergency Medical Technician Emily gained experience as a Clinical Research Co-ordinator at Charles River Clinical Services.
Emily then moved on to work at The Geneva Foundation. At the latter institution Emily gained extensive experience implementing technology-based interventions for the treatment of Combat PTSD (e.g. virtual reality environments, app based support) at Joint Base Lewis-McChord and Fort Bragg installations. Emily also has experience in designing pharmacological interventions for neurological disorders (Traumatic Brain Injury) as well as working on developmental disorders.